Article Text

Download PDFPDF

Original article
Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study
  1. Sanjay K Murthy1,2,3,4,
  2. Jahanara Begum5,
  3. Eric I Benchimol4,5,6,7,8,
  4. Charles N Bernstein9,10,
  5. Gilaad G Kaplan11,12,
  6. Jeffrey D McCurdy1,2,3,
  7. Harminder Singh9,10,
  8. Laura Targownik9,10,
  9. Monica Taljaard3,4
  1. 1Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
  2. 2Division of Gastroenterology, The Ottawa Hospital IBD Centre, Ottawa, Ontario, Canada
  3. 3Clinical Epidemiology Program, OttawaHospital Research Institute, Ottawa, Ontario, Canada
  4. 4School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
  5. 5ICES uOttawa, Ottawa, Ontario, Canada
  6. 6Children’sHospital of Eastern Ontario (CHEO) Inflammatory Bowel Disease Centre, Divisionof Gastroenterology, Hepatology and Nutrition, Ottawa, Ontario, Canada
  7. 7Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada
  8. 8CHEOResearch Institute, Ottawa, Ontario, Canada
  9. 9Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
  10. 10Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada
  11. 11Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
  12. 12Foothills Medical Centre, Division of Gastroenterology and Hepatology, Calgary, Alberta, Canada
  1. Correspondence to Dr Sanjay K Murthy, Department of Medicine, The Ottawa Hospital, University of Ottaw, Ottawa, Ontario K1H 8L6, Canada; smurthy{at}toh.ca

Footnotes

  • Contributors All coauthors made substantial contributions to study design, data interpretation and critical revision of the manuscript for important intellectual content. SKM was most responsible for all aspects of the study, including drafting and finalising the manuscript and all requested revisions. JB was responsible for data acquisition and statistical programming. MT was responsible for guiding the statistical analysis.

  • Funding This study was funded by the Department of Medicine, University of Ottawa and the Canadian Institutes of Health Research (Project Grant # 162393). This study was supported by IC/ES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC).

  • Disclaimer The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. Parts of this paper are based on data and information provided by the Canadian Institute for Health Information (CIHI). No endorsement by ICES, MOHLTC or CIHI is intended or should be inferred.

  • Competing interests COI Statement: SKM has received honoraria for speaking or consultancy from AbbVie, Janssen, Takeda, Pfizer, Shire and Ferring. JB has no conflicts of interest. EIB has no conflicts of interest. CNB has served on advisory boards of AbbVie Canada, Ferring Canada, Janssen Canada, Napo Pharmaceuticals, Pfizer Canada, Shire Canada, Takeda Canada, and has consulted to 4D Pharma and Mylan Pharmaceuticals. He has received unrestricted educational grants from AbbVie Canada, Janssen Canada, Shire Canada and Takeda Canada. He has been on speaker’s bureau of Ferring Canada and Shire Canada. GG has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer and Takeda, and research support from Janssen, AbbVie, GlaxoSmithKline, Merck and Shire. He shares ownership of a patent: Treatment ofInflammatory Disorders, Autoimmune Disease and PBC . UTI Limited Partnership, assignee, Patent 62/555,397, 7 September 2017. JDMcC has received honoraria for speaking or consultancy from AbbVie, Janssen, Takeda, Pfizer, Shire and Ferring. HS has served on advisory boards of Ferring Canada, Takeda Canada, Merck Canada and received research funding from Merck Canada. LT has received research funding from Janssen Canada, and served on advisory boards for AbbVie Canada, Takeda Canada, Merck Canada, Pfizer Canada and Mallinckrodt USA.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The dataset from this study is held securely in coded form at ICES. While data sharing agreements prohibit ICES from making the dataset publicly available, access may be granted to those who meet prespecified criteria for confidential access, available at http://www.ices.on.ca/DAS. The full dataset creation plan and underlying analytic code are available from the authors on request, understanding that the computer programs may rely on coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

  • Correction notice This article has been corrected since it published Online First. The disclaimer statement, figure 2 legend and significance of this study box has been updated.

  • Patient consent for publication Not required.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All coauthors made substantial contributions to study design, data interpretation and critical revision of the manuscript for important intellectual content. SKM was most responsible for all aspects of the study, including drafting and finalising the manuscript and all requested revisions. JB was responsible for data acquisition and statistical programming. MT was responsible for guiding the statistical analysis.

  • Funding This study was funded by the Department of Medicine, University of Ottawa and the Canadian Institutes of Health Research (Project Grant # 162393). This study was supported by IC/ES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC).

  • Disclaimer The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. Parts of this paper are based on data and information provided by the Canadian Institute for Health Information (CIHI). No endorsement by ICES, MOHLTC or CIHI is intended or should be inferred.

  • Competing interests COI Statement: SKM has received honoraria for speaking or consultancy from AbbVie, Janssen, Takeda, Pfizer, Shire and Ferring. JB has no conflicts of interest. EIB has no conflicts of interest. CNB has served on advisory boards of AbbVie Canada, Ferring Canada, Janssen Canada, Napo Pharmaceuticals, Pfizer Canada, Shire Canada, Takeda Canada, and has consulted to 4D Pharma and Mylan Pharmaceuticals. He has received unrestricted educational grants from AbbVie Canada, Janssen Canada, Shire Canada and Takeda Canada. He has been on speaker’s bureau of Ferring Canada and Shire Canada. GG has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer and Takeda, and research support from Janssen, AbbVie, GlaxoSmithKline, Merck and Shire. He shares ownership of a patent: Treatment ofInflammatory Disorders, Autoimmune Disease and PBC . UTI Limited Partnership, assignee, Patent 62/555,397, 7 September 2017. JDMcC has received honoraria for speaking or consultancy from AbbVie, Janssen, Takeda, Pfizer, Shire and Ferring. HS has served on advisory boards of Ferring Canada, Takeda Canada, Merck Canada and received research funding from Merck Canada. LT has received research funding from Janssen Canada, and served on advisory boards for AbbVie Canada, Takeda Canada, Merck Canada, Pfizer Canada and Mallinckrodt USA.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The dataset from this study is held securely in coded form at ICES. While data sharing agreements prohibit ICES from making the dataset publicly available, access may be granted to those who meet prespecified criteria for confidential access, available at http://www.ices.on.ca/DAS. The full dataset creation plan and underlying analytic code are available from the authors on request, understanding that the computer programs may rely on coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

  • Correction notice This article has been corrected since it published Online First. The disclaimer statement, figure 2 legend and significance of this study box has been updated.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.